Buwenge Milly, Cilla Savino, Guido Alessandra, Giaccherini Lucia, Macchia Gabriella, Deodato Francesco, Cammelli Silvia, Cellini Francesco, Mattiucci Gian C, Valentini Vincenzo, Stock Markus, Morganti Alessio G
Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy.
Medical Physic Unit, Fondazione "Giovanni Paolo II", Catholic University of Sacred Heart, Campobasso, Italy.
Rep Pract Oncol Radiother. 2016 Nov-Dec;21(6):548-554. doi: 10.1016/j.rpor.2016.09.003. Epub 2016 Sep 28.
Aim of this study was to perform a planning feasibility analysis of a 3-level dose prescription using an IMRT-SIB technique.
Radiation therapy of locally advanced pancreatic cancer should administer a minimum dose to the duodenum and a very high dose to the vascular infiltration areas to improve the possibility of a radical resection.
Fifteen patients with pancreatic head adenocarcinoma and vascular involvement were included. The duodenal PTV (PTVd) was defined as the GTV overlapping the duodenal PRV. Vascular CTV (CTVv) was defined as the surface of contact or infiltration between the tumor and vessel plus a 5 mm margin. Vascular PTV (PTVv) was considered as the CTVv plus an anisotropic margin. The tumor PTV (PTVt) was defined as the GTV plus a margin including the PTVv and excluding the PTVd. The following doses were prescribed: 30 Gy (6 Gy/fraction) to PTVd, 37.5 Gy (7.5 Gy/fraction) to PTVt, and 45 Gy (9 Gy/fraction) to PTVv, respectively. Treatment was planned with an IMRT technique.
The primary end-point (PTVv > 90%) was achieved in all patients. PTVv > 90% was achieved in 6 patients (40%). OARs constraints were achieved in all patients.
Although the PTVv > 95% objective was achieved only in 40% of patients, the study showed that in 100% of patients it was possible to administer a strongly differentiated mean/median dose. Prospective trials based on clinical application of this strategy seem to be justified in selected patients without overlap between PTVd and PTVv.
本研究的目的是使用调强适形放疗同步整合加量(IMRT-SIB)技术对三级剂量处方进行计划可行性分析。
局部晚期胰腺癌的放射治疗应给予十二指肠最低剂量,并给予血管浸润区域非常高的剂量,以提高根治性切除的可能性。
纳入15例胰头腺癌伴血管受累患者。十二指肠计划靶体积(PTVd)定义为与十二指肠计划风险体积(PRV)重叠的大体肿瘤体积(GTV)。血管临床靶体积(CTVv)定义为肿瘤与血管之间的接触或浸润表面加上5毫米的边界。血管计划靶体积(PTVv)被视为CTVv加上各向异性边界。肿瘤计划靶体积(PTVt)定义为GTV加上一个边界,包括PTVv且不包括PTVd。分别给予以下剂量:PTVd为30 Gy(6 Gy/分次),PTVt为37.5 Gy(7.5 Gy/分次),PTVv为45 Gy(9 Gy/分次)。采用IMRT技术进行治疗计划。
所有患者均达到主要终点(PTVv>90%)。6例患者(40%)达到PTVv>90%。所有患者均达到危及器官限制。
尽管仅40%的患者达到PTVv>95%的目标,但该研究表明,100%的患者有可能给予高度差异化的平均/中位剂量。基于该策略临床应用的前瞻性试验似乎在PTVd和PTVv无重叠的特定患者中是合理的。